The Ross Procedure in Adults: Long-Term Results of Homografts and Stentless Xenografts for Pulmonary Valve Replacement
23 April 2016
10 June 2016
10 August 2016 (online)
Background The Ross procedure is an established method to treat aortic valve disease, offering excellent hemodynamic characteristics, growth potential, low risk of thromboembolism and no need for anticoagulation. Limitation of homograft quality and availability led to the use of different stentless xenografts. Long-term outcome and implications are yet to be addressed.
Methods Forty five adult patients (mean age 38.8 ± 9.6 years) with aortic valve stenosis and/or insufficiency, who underwent the Ross procedure between 1995 and 2002 were identified for long-term evaluation. Patients younger than 18 years, with previous heart surgery and endocarditis were excluded. Stentless xenografts were used in 22 cases (Group X) and homografts in 23 cases (Group H). After review of the patients' history, morbidity and mortality were analyzed and risk stratification was performed.
Results Between groups, baseline characteristics and operative data did not differ significantly. Total follow-up was 621.0 patient-years and 98.8% complete. Overall freedom from reoperation at 15 years was 68.4 ± 10.6% in group X and 85. ± 7.9% in group H (p = 0.09), respectively. Freedom from aortic valve reoperation at 15 years was comparable (83.9 ± 8.5% in group X and 85.3 ± 7.9% in group H, p = 0.61), whereas freedom from pulmonary valve reoperation at 15 years was significantly lower in group X (78.9 ± 9.4% versus 100%, p = 0.02). Long-term survival at 15 years was 79.7 ± 9.3% in group X and 94.4 ± 5.4% in group H (p = 0.07), respectively.
Conclusions Stentless xenografts used as pulmonary valve substitute in the Ross procedure led to lower freedom from pulmonary valve reoperation compared with homografts. Additionally, there was a trend to inferior long-term survival with xenografts. Therefore, homografts should remain the preferred option for pulmonary valve replacement in the Ross procedure.
- 1 Ross DN. Replacement of aortic and mitral valves with a pulmonary autograft. Lancet 1967; 2 (7523): 956-958
- 2 Chambers JC, Somerville J, Stone S, Ross DN. Pulmonary autograft procedure for aortic valve disease: long-term results of the pioneer series. Circulation 1997; 96 (07) 2206-2214
- 3 Kouchoukos NT, Masetti P, Nickerson NJ, Castner CF, Shannon WD, Dávila-Román VG. The Ross procedure: long-term clinical and echocardiographic follow-up. Ann Thorac Surg 2004; 78 (03) 773-781 , discussion 773–781
- 4 Nishimura RA, Otto CM, Bonow RO. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (22) e57-e185
- 5 Elkins RC, Knott-Craig CJ, Ward KE, McCue C, Lane MM. Pulmonary autograft in children: realized growth potential. Ann Thorac Surg 1994; 57 (06) 1387-1393 , discussion 1393–1394
- 6 Reece TB, Welke KF, O'Brien S, Grau-Sepulveda MV, Grover FL, Gammie JS. Rethinking the ross procedure in adults. Ann Thorac Surg 2014; 97 (01) 175-181
- 7 Carr-White GS, Kilner PJ, Hon JK. , et al. Incidence, location, pathology, and significance of pulmonary homograft stenosis after the Ross operation. Circulation 2001; 104 (12) (Suppl. 01) I16-I20
- 8 Konertz W, Sidiropoulos A, Hotz H, Borges A, Baumann G. Ross operation and right ventricular outflow tract reconstruction with stentless xenografts. J Heart Valve Dis 1996; 5 (04) 418-420
- 9 Schmid FX, Keyser A, Wiesenack C, Holmer S, Birnbaum DE. Stentless xenografts and homografts for right ventricular outflow tract reconstruction during the Ross operation. Ann Thorac Surg 2002; 74 (03) 684-688
- 10 Konertz W, Dohmen PM, Liu J. , et al. Hemodynamic characteristics of the Matrix P decellularized xenograft for pulmonary valve replacement during the Ross operation. J Heart Valve Dis 2005; 14 (01) 78-81
- 11 Miskovic A, Monsefi N, Doss M, Özaslan F, Karimian A, Moritz A. Comparison between homografts and Freestyle® bioprosthesis for right ventricular outflow tract replacement in Ross procedures. Eur J Cardiothorac Surg 2012; 42 (06) 927-933
- 12 Hechadi J, Gerber BL, Coche E. , et al. Stentless xenografts as an alternative to pulmonary homografts in the Ross operation. Eur J Cardiothorac Surg 2013; 44 (01) e32-e39
- 13 Akins CW, Miller DC, Turina MI. , et al; Councils of the American Association for Thoracic Surgery; Society of Thoracic Surgeons; European Assoication for Cardio-Thoracic Surgery; Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 2008; 135 (04) 732-738
- 14 Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48 (12) 1503-1510
- 15 Sievers H-H, Stierle U, Charitos EI. , et al. A multicentre evaluation of the autograft procedure for young patients undergoing aortic valve replacement: update on the German Ross Registry. Eur J Cardiothorac Surg 2016; 49: 212-218
- 16 Weymann A, Dohmen PM, Grubitzsch H, Dushe S, Holinski S, Konertz W. Clinical experience with expanded use of the Ross procedure: a paradigm shift?. J Heart Valve Dis 2010; 19 (03) 279-285
- 17 Chiang YP, Chikwe J, Moskowitz AJ, Itagaki S, Adams DH, Egorova NN. Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA 2014; 312 (13) 1323-1329
- 18 Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36 (04) 1152-1158
- 19 David TE, David C, Woo A, Manlhiot C. The Ross procedure: outcomes at 20 years. J Thorac Cardiovasc Surg 2014; 147 (01) 85-93
- 20 Ruel M, Kulik A, Lam BK. , et al. Long-term outcomes of valve replacement with modern prostheses in young adults. Eur J Cardiothorac Surg 2005; 27 (03) 425-433 , discussion 433
- 21 Christ T, Grubitzsch H, Claus B, Konertz W. Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age. J Thorac Cardiovasc Surg 2014; 147 (01) 264-269
- 22 Christ T, Grubitzsch H, Claus B, Konertz W. Stentless aortic valve replacement in the young patient: long-term results. J Cardiothorac Surg 2013; 8: 68
- 23 Isaacs AJ, Shuhaiber J, Salemi A, Isom OW, Sedrakyan A. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg 2015; 149 (05) 1262-9.e3